• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    L

    Lublin Oncology Center

    115论文总数
    621引用总数

    论文量&引用量时间轴

    机构学者

    论文(115)

    年份
    起
    –
    止
    排序
    1Low PHASES-Estimated Rupture Risk among Patients Presenting with Ruptured Intracranial Aneurysms: A Retrospective Single-Centre Observational Study
    Mateusz Krakowiak, Bartlomiej Kulesza, Cezary Grochowski, Barbara Maria Myszkowska, Damian Palus,Agnieszka Brzozowska, Pawel Sokal

    Background/Objectives: The PHASES score is widely used to estimate the 5-year rupture risk of unruptured intracranial aneurysms, yet many patients present with aneurysmal subarachnoid haemorrhage despite low calculated risk. This study aimed to characterise the demographic and aneurysm-related profile of patients with ruptured aneurysms classified as low risk by PHASES. Methods: This retrospective single-centre observational study included 243 consecutive patients with radiologically confirmed ruptured intracranial aneurysms treated between 2013 and 2021. PHASES scores and estimated 5-year rupture risks were calculated retrospectively. Age, sex, arterial hypertension, aneurysm size, location, and multiplicity were analysed using non-parametric statistical methods. Results: The mean PHASES score was 5.16 +/- 3.43 points. An estimated 5-year rupture risk below 1% was assigned to 125 patients (51.44%), and 54 patients (22.22%) had PHASES scores of 0-2. Ruptured aneurysms measuring <= 7 mm occurred in 147 patients (60.49%), and 210 patients (86.42%) were younger than 70 years. Internal carotid artery aneurysms were the most frequent overall, whereas anterior communicating artery aneurysms had the smallest median diameter while remaining among the most common rupture sites. Arterial hypertension was associated with larger aneurysm diameter. Conclusions: Low PHASES-estimated risks were common in this cohort of patients presenting with aneurysm rupture. Because the study included no comparison group with unruptured aneurysms, it cannot assess PHASES calibration or predictive performance. PHASES should therefore be used as a population-based decision-support tool rather than a stand-alone predictor of individual rupture risk, with morphology, imaging findings, documented growth, and patient-specific factors incorporated into clinical assessment.

    2026JOURNAL OF CLINICAL MEDICINE(2026)
    引用
    AI阅读
    加入学术空间
    2Chemotherapy Regimen and Cisplatin Dose Effects on Survival in Neoadjuvant Treatment of Urothelial Muscle-Invasive Bladder Cancer.
    Mateusz Malik, Maciej Rozycki, Zbyszko Chowaniec,Marek Gelej, Jacek Ornat, Krzysztof Tupikowski,Adam Maciejczyk, Piotr Jacyk,Barbara Radecka, Dawid Sigorski, Tomasz Lewandowski, Katarzyna Czerko,

    e16579 Background: Neoadjuvant chemotherapy (NACT) in patients (pts) with muscle-invasive bladder cancer (MIBC) significantly improves treatment outcomes. Widely used NACT regimen based on 3-4 cycles of gemcitabine and cisplatin (GC) before radical cystectomy (RC) remained the standard of care until the complete results of the VESPER trial, which demonstrated the superiority of 6 cycles of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in terms of progression-free survival (PFS), complete pathological responses (pCR) and overall survival (OS). In most clinical trials, pts with clinically positive lymph nodes (N+ according to TMN) were underrepresented. The aim of the study is to compare the effectiveness and safety of the mentioned NACT regimens in real medical practice. Methods: Pts from 7 urooncology hospitals in Poland with MIBC stage ≥T2, cM0 treated with NACT GC or ddMVAC (11/2016-09/2024) were included. Pts from clinical trials were excluded. Complete clinical data were collected. Survival analyses were performed using the Kaplan-Meier method, Log-rank and chi-square or Fisher's tests were used for comparison between groups. Data cut-off was 31/12/2024. Results: Of the 261 pts treated with NACT, 232 were included in the analysis: 132 (57%) received GC, 100 (43%) ddMVAC). There were 55 (24%) women in the study groups, the median age was 67, cT2N0: 90 (39%), N+: 61 (27%), baseline anemia of any grade: 107 (48%). In the GC group, there were significantly more ECOG performance status (PS) 2 pts, p=0.0076, other variables did not differ significantly. Median total dose of cisplatin (MTDC) was significantly higher in ddMVAC group than in GC group (280 vs 210 mg/m2), p=0.0024. Median chemotherapy period was significantly longer in GC pts: 9 vs 6.3 weeks for ddMVAC, p=0.0007. RC was not performed in 35 (15%) of pts due to adverse events (AEs), progression, or withdrawal of consent. More objective pathological responses were achieved in the ddMVAC vs GC pts, 42 vs 14%, p<0,0001, however, there were no differences in clinical response. Significant difference in mOS between GP and ddMVAC group was observed: 27 vs 39m, p=0.0203. In univariate analysis, a significant advantage was also observed for MTDC ≥250mg/m2, p=0.0093; ECOG PS 0, p=0.0018; RC, p=0.01; R0 resection, p=0.001; and pCR, p<0.0001 in terms of OS. OS did not differ significantly between cT2N0 or >cT2N0 pts, p=0.3. Multivariate analysis confirmed a statistically significant OS benefit for ECOG PS 0, higher MDTC and pCR. More hematological AEs occured in the GC vs ddMVAC group: 98% vs 84%, p=0.0007. Conclusions: The use of NACT with the ddMVAC in MIBC pts showed a statistically significant improvement of OS compared to GC with favorable toxicity. The study indicates that the best prognosis is for pts with ECOG PS 0 who received a higher MTDC (preferably in the ddMVAC regimen), responded to NACT and underwent radical surgery regardless of the primary clinical stage of T and N.

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)引用:1
    引用
    AI阅读
    加入学术空间
    3Late Sequelae of Hodgkin Lymphoma Treatment in Polish Childhood Cancer Survivors.
    K. Kononczuk,K. Muszynska-Roslan,M. Krawczuk-Rybak,M. Zubowska,W. Mlynarski, T. Stachowicz-Stencel,J. Stefanowicz, D. Slawinska,K. Drabko,J. Skalska-Sadowska,K. Derwich,W. Badowska,
    2025KLINISCHE PADIATRIE(2025)
    引用
    AI阅读
    加入学术空间
    4WHOLE-BODY AND PARTIAL-BODY CRYOTHERAPY: A REVIEW OF MECHANISMS, APPLICATIONS, AND SAFETY
    Aleksander Białoń, Paweł Harbut, Dominika Walczak, Weronika Ewa Nowak, Adrian Kruk, Katarzyna Jakubowska, Aleksandra Dorosz, Igor Gawłowski, Aleksandra Miśta, Lidia Jurczenko

    Introduction: Cryotherapy, encompassing whole-body cryotherapy (WBC) and partial-body cryotherapy (PBC), has gained increasing attention in sports, medicine, rehabilitation, and wellness for its potential anti-inflammatory, analgesic, and recovery-enhancing effects. Originally developed in Japan in the late 1970s for the treatment of rheumatoid arthritis, WBC has since evolved into a multidisciplinary therapeutic modality with a wide range of clinical and non-clinical applications. Materials and Methods: A systematic literature search of PubMed and Embase from 2013–2025 was conducted using the terms “cryotherapy,” “whole-body cryotherapy,” and “cryostimulation.” Results: The evidence suggests that WBC elicits systemic anti-inflammatory effects through modulation of cytokines (e.g., decreased IL-1β, TNF-α, and hsCRP; increased IL-10), enhances antioxidant enzyme activity, and improves markers of oxidative stress. Clinical data further indicate beneficial outcomes in conditions such as rheumatic and osteoarticular diseases, fibromyalgia, multiple sclerosis, mood disorders, chronic pain, and obesity. WBC may also support athletic recovery by reducing muscle soreness and improving performance adaptation. Despite its broad therapeutic potential, contraindications, including cardiovascular, neurological, and cold-related disorders, must be observed. Reported adverse effects are generally mild and transient. Conclusions: Overall, cryotherapy appears to be a promising adjunctive modality, though further controlled studies are warranted to establish standardised treatment protocols and confirm long-term safety and efficacy.

    2025International Journal of Innovative Technologies in Social Science(2025)
    引用
    AI阅读
    加入学术空间
    5A Populational Change in Prognosis of Patients Diagnosed with Locally Advanced Melanoma: Last Glimpse Before the Introduction of Adjuvant Treatment in Stage IIB/C.
    Pawel Teterycz,Katarzyna Kozak,Marcin Zietek,Marcin Zdzienicki, Magdalena Papiez,Grazyna Kaminska-Winciorek, Katarzyna Galwas, Natasza Kempa-Kaminska,Bozena Cybulska-Stopa,Lukasz Galus, Robert Dziura,Dariusz Nejc,

    e21575 Background: The treatment of early-stage melanoma is rapidly changing. Recent advancements include neoadjuvant treatment in stage III clinically detected disease and adjuvant treatment in stage IIB/C melanoma. In particular, adjuvant immunotherapy for IIB/C disease has become recently available. We took this opportunity to evaluate changes in outcomes in patients diagnosed with stage II and III melanoma. Methods: We have analyzed the accessible, retrospective data on patients diagnosed with melanoma between 2015 and 2022 who underwent sentinel lymph node biopsy or therapeutic lymph node dissection in high-throughput centers in Poland. The data on primary staging, patients’ demographics, and information on follow-up and overall survival (OS) were collected. A prespecified OS Cox model with non-linear terms for age, sex, stage (II vs. III), and availability of adjuvant treatment in stage III (i.e., since 2021) was fitted. Results: There were 1970 patients (45.2% female) included in this analysis. The mean age was 62 (range:14-97). The exact stage distribution and 3-year OS rates are presented in Table 1. Patients diagnosed with stage III melanoma before 2021 had worse prognoses than stage II patients (HR: 1.33, 95%CI: 1.11-1.60, p=0.002). Since then the prognosis for stage II patients did not improve (HR: 1.13, 95%CI: 0.89-1.45, p=0.325) while the prognosis in stage III melanoma became similar to stage II after the introduction of adjuvant therapy (HR: 1.09, 95% CI: 0.78-1.53, p = 0.607). Conclusions: The introduction of adjuvant treatment improved the OS of stage III melanoma patients in this nationwide study. The modern prognosis is similar to patients with stage II melanoma without adjuvant treatment, with excellent results in stage IIIA/IIIB cases. The practitioners should be cautious when discussing historical prognosis with their patients and it implies the necessity of changes in AJCC staging. Stage distribution and 3-year survival rates. Stage Number of patients Percentage of group 3 year survial rate (%) 95% Confidence Interval (%) IIA 352 17.9 86.5 82.9 - 90.3 IIB 378 19.2 76.5 72.2 - 81.2 IIC 443 22.5 59.9 55.3 - 64.8 IIIA 84 4.3 94.3 89.1 - 99.9 IIIB 132 6.7 94.6 90.5 - 98.9 IIIC 518 26.3 68.5 64.3 - 73.1 IIID 63 3.2 53.3 42.2 - 67.4

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 115 篇论文

    合作机构(100)

    Medical University of Lublin合作论文 20
    Gdańsk Medical University合作论文 8
    Poznan University of Medical Sciences合作论文 6
    Maria Sklodowska-Curie National Research Institute of Oncology合作论文 6
    Nicolaus Copernicus University合作论文 4
    Wojskowy Instytut Medycyny Lotniczej合作论文 4
    Medical University of Lodz合作论文 4
    华沙医科大学合作论文 3
    Masaryk Memorial Cancer Institute合作论文 3
    Greater Poland Cancer Center合作论文 3

    机构统计